JP2020514334A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514334A5 JP2020514334A5 JP2019547663A JP2019547663A JP2020514334A5 JP 2020514334 A5 JP2020514334 A5 JP 2020514334A5 JP 2019547663 A JP2019547663 A JP 2019547663A JP 2019547663 A JP2019547663 A JP 2019547663A JP 2020514334 A5 JP2020514334 A5 JP 2020514334A5
- Authority
- JP
- Japan
- Prior art keywords
- trans
- cyclohexyl
- methyl
- phenyl
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 full Ranil Chemical group 0.000 claims 90
- PNZXMIKHJXIPEK-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1CCCCC1 PNZXMIKHJXIPEK-UHFFFAOYSA-N 0.000 claims 28
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 24
- 239000012453 solvate Substances 0.000 claims 24
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 229910052805 deuterium Inorganic materials 0.000 claims 21
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 17
- JTNNVONTXCBLEJ-UHFFFAOYSA-N cyclohexylmethyl carbamate Chemical compound NC(=O)OCC1CCCCC1 JTNNVONTXCBLEJ-UHFFFAOYSA-N 0.000 claims 16
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 12
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 9
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 7
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 6
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 5
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 5
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 5
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 4
- MQGJTSVKWXWUEJ-UHFFFAOYSA-N 4-N-[3-(2-methoxy-1,3-thiazol-5-yl)phenyl]cyclohexane-1,4-dicarboxamide Chemical compound COC1=NC=C(S1)C2=CC(=CC=C2)NC(=O)C3CCC(CC3)C(=O)N MQGJTSVKWXWUEJ-UHFFFAOYSA-N 0.000 claims 4
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims 4
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 4
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 4
- 241000711549 Hepacivirus C Species 0.000 claims 4
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 4
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- VZFUCHSFHOYXIS-UHFFFAOYSA-N cycloheptane carboxylic acid Natural products OC(=O)C1CCCCCC1 VZFUCHSFHOYXIS-UHFFFAOYSA-N 0.000 claims 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 210000004185 liver Anatomy 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 4
- 125000003944 tolyl group Chemical group 0.000 claims 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims 3
- XSJOKZKOSJKFOQ-UHFFFAOYSA-N cyclohexyl 3-hydroxyazetidine-1-carboxylate Chemical compound OC1CN(C1)C(=O)OC1CCCCC1 XSJOKZKOSJKFOQ-UHFFFAOYSA-N 0.000 claims 3
- 208000006454 hepatitis Diseases 0.000 claims 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 3
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 claims 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- INNWRDCESBMSQK-UHFFFAOYSA-N 2-(2-hydroxyethoxy)acetamide Chemical compound NC(=O)COCCO INNWRDCESBMSQK-UHFFFAOYSA-N 0.000 claims 2
- 206010004659 Biliary cirrhosis Diseases 0.000 claims 2
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 claims 2
- 208000015943 Coeliac disease Diseases 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 208000004232 Enteritis Diseases 0.000 claims 2
- 241000700721 Hepatitis B virus Species 0.000 claims 2
- 206010019799 Hepatitis viral Diseases 0.000 claims 2
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 208000018839 Wilson disease Diseases 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- GTCAXTIRRLKXRU-UHFFFAOYSA-N carbamic acid methyl ester Natural products COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000003566 oxetanyl group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 201000001862 viral hepatitis Diseases 0.000 claims 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims 1
- ASTRWPOSIDFRGD-UHFFFAOYSA-N 2-(1h-imidazol-2-yl)acetamide Chemical compound NC(=O)CC1=NC=CN1 ASTRWPOSIDFRGD-UHFFFAOYSA-N 0.000 claims 1
- BRTQKGICBJYPER-UHFFFAOYSA-N 2-(1h-imidazol-5-yl)acetamide Chemical compound NC(=O)CC1=CNC=N1 BRTQKGICBJYPER-UHFFFAOYSA-N 0.000 claims 1
- XRVGAZQKAXSYSB-UHFFFAOYSA-N 2-(2-aminoethoxy)acetamide Chemical compound NCCOCC(N)=O XRVGAZQKAXSYSB-UHFFFAOYSA-N 0.000 claims 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 1
- WKJOQYHMXRVQDK-UHFFFAOYSA-N 2-(dimethylamino)acetamide Chemical compound CN(C)CC(N)=O WKJOQYHMXRVQDK-UHFFFAOYSA-N 0.000 claims 1
- ILISJYDKHMRJLS-UHFFFAOYSA-N 2-[2-(dimethylamino)ethoxy]acetamide Chemical compound CN(C)CCOCC(N)=O ILISJYDKHMRJLS-UHFFFAOYSA-N 0.000 claims 1
- WQELDIQOHGAHEM-UHFFFAOYSA-N 2-acetamidoacetamide Chemical compound CC(=O)NCC(N)=O WQELDIQOHGAHEM-UHFFFAOYSA-N 0.000 claims 1
- DRYMMXUBDRJPDS-UHFFFAOYSA-N 2-hydroxy-2-methylpropanamide Chemical compound CC(C)(O)C(N)=O DRYMMXUBDRJPDS-UHFFFAOYSA-N 0.000 claims 1
- TZGPACAKMCUCKX-UHFFFAOYSA-N 2-hydroxyacetamide Chemical compound NC(=O)CO TZGPACAKMCUCKX-UHFFFAOYSA-N 0.000 claims 1
- MEAVLRNBGURMFI-UHFFFAOYSA-N 2-imidazol-1-ylacetamide Chemical compound NC(=O)CN1C=CN=C1 MEAVLRNBGURMFI-UHFFFAOYSA-N 0.000 claims 1
- 125000001137 3-hydroxypropoxy group Chemical group [H]OC([H])([H])C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- AHWKKJBPRHKEAZ-BBHPTNJDSA-N C(C)(=O)OCC(=O)N[C@@H]1CC[C@H](CC1)C(N(C[C@@H]1CC[C@H](CC1)C1=CC(=C(C=C1)OC)C)C1=CC(=CC=C1)C1=CN=C(S1)C1CC1)=O Chemical compound C(C)(=O)OCC(=O)N[C@@H]1CC[C@H](CC1)C(N(C[C@@H]1CC[C@H](CC1)C1=CC(=C(C=C1)OC)C)C1=CC(=CC=C1)C1=CN=C(S1)C1CC1)=O AHWKKJBPRHKEAZ-BBHPTNJDSA-N 0.000 claims 1
- VMDKSZYJGUQOTM-GJIFKWMDSA-N C1(CC1)C=1OC=C(N=1)C=1C=C(C=CC=1)N(C(=O)[C@@H]1CC[C@H](CC1)C(=O)O)C[C@@H]1CC[C@H](CC1)C1=NC(=C(C=C1)OC)C Chemical compound C1(CC1)C=1OC=C(N=1)C=1C=C(C=CC=1)N(C(=O)[C@@H]1CC[C@H](CC1)C(=O)O)C[C@@H]1CC[C@H](CC1)C1=NC(=C(C=C1)OC)C VMDKSZYJGUQOTM-GJIFKWMDSA-N 0.000 claims 1
- ZLSKXUNGURIOPO-PJMRXRQGSA-N C1(CC1)C=1SC(=CN=1)C=1C=C(C=CC=1)N(C(=O)[C@@H]1CC[C@H](CC1)C(=O)O)C[C@@H]1CC[C@H](CC1)C1=CC(=C(C=C1)OC)C Chemical compound C1(CC1)C=1SC(=CN=1)C=1C=C(C=CC=1)N(C(=O)[C@@H]1CC[C@H](CC1)C(=O)O)C[C@@H]1CC[C@H](CC1)C1=CC(=C(C=C1)OC)C ZLSKXUNGURIOPO-PJMRXRQGSA-N 0.000 claims 1
- JGCVCDZUKPGRJH-GJIFKWMDSA-N C1(CC1)C=1SC(=CN=1)C=1C=C(C=CC=1)N(C(=O)[C@@H]1CC[C@H](CC1)C(=O)O)C[C@@H]1CC[C@H](CC1)C1=NC(=C(C=C1)OC)C Chemical compound C1(CC1)C=1SC(=CN=1)C=1C=C(C=CC=1)N(C(=O)[C@@H]1CC[C@H](CC1)C(=O)O)C[C@@H]1CC[C@H](CC1)C1=NC(=C(C=C1)OC)C JGCVCDZUKPGRJH-GJIFKWMDSA-N 0.000 claims 1
- DUYVQFALZIQYEW-ZKHCSVRISA-N C1(CC1)C=1SC(=CN=1)C=1C=C(C=CC=1)N(C(=O)[C@@H]1CC[C@H](CC1)C(=O)O)C[C@@H]1CC[C@H](CC1)C=1C=C2C(=NN(C2=CC=1)C)F Chemical compound C1(CC1)C=1SC(=CN=1)C=1C=C(C=CC=1)N(C(=O)[C@@H]1CC[C@H](CC1)C(=O)O)C[C@@H]1CC[C@H](CC1)C=1C=C2C(=NN(C2=CC=1)C)F DUYVQFALZIQYEW-ZKHCSVRISA-N 0.000 claims 1
- KEHLVXSDNNLLBB-GJIFKWMDSA-N C1(CC1)C=1SC(=CN=1)C=1C=C(C=CC=1)N(C(=O)[C@@H]1CC[C@H](CC1)C(=O)O)C[C@@H]1CC[C@H](CC1)C=1C=NC(=CC=1)N(C)C Chemical compound C1(CC1)C=1SC(=CN=1)C=1C=C(C=CC=1)N(C(=O)[C@@H]1CC[C@H](CC1)C(=O)O)C[C@@H]1CC[C@H](CC1)C=1C=NC(=CC=1)N(C)C KEHLVXSDNNLLBB-GJIFKWMDSA-N 0.000 claims 1
- FZVABQMKLCITEZ-DUOCIXOMSA-N C1(CC1)N1N=CC(=C1)C=1C=C(C=CC=1)N(C(=O)[C@@H]1CC[C@H](CC1)C(=O)O)C[C@@H]1CC[C@H](CC1)C1=CC(=C(C=C1)OC)C Chemical compound C1(CC1)N1N=CC(=C1)C=1C=C(C=CC=1)N(C(=O)[C@@H]1CC[C@H](CC1)C(=O)O)C[C@@H]1CC[C@H](CC1)C1=CC(=C(C=C1)OC)C FZVABQMKLCITEZ-DUOCIXOMSA-N 0.000 claims 1
- BHJPSCZFVRKCKA-KKLUKGEUSA-N C1(CC1)N1N=CC(=C1)C=1C=C(C=CC=1)N(C(=O)[C@@H]1CC[C@H](CC1)C(=O)O)C[C@@H]1CC[C@H](CC1)C1=NC(=C(C=C1)OC)C Chemical compound C1(CC1)N1N=CC(=C1)C=1C=C(C=CC=1)N(C(=O)[C@@H]1CC[C@H](CC1)C(=O)O)C[C@@H]1CC[C@H](CC1)C1=NC(=C(C=C1)OC)C BHJPSCZFVRKCKA-KKLUKGEUSA-N 0.000 claims 1
- HEKPYFGSPLCSCQ-KKLUKGEUSA-N C1(CC1)N1N=CC(=C1)C=1C=C(C=CC=1)N(C(=O)[C@@H]1CC[C@H](CC1)C(=O)O)C[C@@H]1CC[C@H](CC1)C=1C=NC(=CC=1)N(C)C Chemical compound C1(CC1)N1N=CC(=C1)C=1C=C(C=CC=1)N(C(=O)[C@@H]1CC[C@H](CC1)C(=O)O)C[C@@H]1CC[C@H](CC1)C=1C=NC(=CC=1)N(C)C HEKPYFGSPLCSCQ-KKLUKGEUSA-N 0.000 claims 1
- WWPBGRFNTNUPJL-UHFFFAOYSA-N CNC(=O)C1CCC(CC1)(C2=CC=CC(=C2)C3=CN=C(S3)OC)C(=O)N Chemical compound CNC(=O)C1CCC(CC1)(C2=CC=CC(=C2)C3=CN=C(S3)OC)C(=O)N WWPBGRFNTNUPJL-UHFFFAOYSA-N 0.000 claims 1
- IFXXQWHPKYXHBF-NGUIPBPISA-N CNC(OCC(=O)N[C@@H]1CC[C@H](CC1)C(N(C[C@@H]1CC[C@H](CC1)C1=CC(=C(C=C1)OC)C)C1=CC(=CC=C1)C1=CN=C(S1)C1CC1)=O)=O Chemical compound CNC(OCC(=O)N[C@@H]1CC[C@H](CC1)C(N(C[C@@H]1CC[C@H](CC1)C1=CC(=C(C=C1)OC)C)C1=CC(=CC=C1)C1=CN=C(S1)C1CC1)=O)=O IFXXQWHPKYXHBF-NGUIPBPISA-N 0.000 claims 1
- RUZBEQCLWXMRMX-OLJJXAFESA-N CNC(OCC(=O)N[C@@H]1CC[C@H](CC1)C(N(C[C@@H]1CC[C@H](CC1)C1=CC(=C(C=C1)OC)C)C1=CC(=CC=C1)C=1C=NN(C=1)C1CC1)=O)=O Chemical compound CNC(OCC(=O)N[C@@H]1CC[C@H](CC1)C(N(C[C@@H]1CC[C@H](CC1)C1=CC(=C(C=C1)OC)C)C1=CC(=CC=C1)C=1C=NN(C=1)C1CC1)=O)=O RUZBEQCLWXMRMX-OLJJXAFESA-N 0.000 claims 1
- OQZOFICNCLYFHN-VJODKUTPSA-N COC1=C(C=C(C=C1)[C@@H]1CC[C@H](CC1)CN(C(=O)C12CCC(CC1)(CC2)C(=O)O)C1=CC(=CC=C1)C1=CN=C(S1)OC)C Chemical compound COC1=C(C=C(C=C1)[C@@H]1CC[C@H](CC1)CN(C(=O)C12CCC(CC1)(CC2)C(=O)O)C1=CC(=CC=C1)C1=CN=C(S1)OC)C OQZOFICNCLYFHN-VJODKUTPSA-N 0.000 claims 1
- DSPZSZBYTKYIOA-YROJFRDXSA-N COC1=C(C=C(C=C1)[C@@H]1CC[C@H](CC1)CN(C(=O)[C@@H]1CC[C@H](CC1)C(=O)O)C1=CC(=CC=C1)C1=CN=C(S1)OC)C Chemical compound COC1=C(C=C(C=C1)[C@@H]1CC[C@H](CC1)CN(C(=O)[C@@H]1CC[C@H](CC1)C(=O)O)C1=CC(=CC=C1)C1=CN=C(S1)OC)C DSPZSZBYTKYIOA-YROJFRDXSA-N 0.000 claims 1
- MJCLTXDNEBGPNR-UHFFFAOYSA-N CS(=O)(=O)NC(=O)C1CCC(CC1)C(=O)N Chemical compound CS(=O)(=O)NC(=O)C1CCC(CC1)C(=O)N MJCLTXDNEBGPNR-UHFFFAOYSA-N 0.000 claims 1
- 208000005623 Carcinogenesis Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 206010008635 Cholestasis Diseases 0.000 claims 1
- 101150065749 Churc1 gene Proteins 0.000 claims 1
- MJOSTMRKWHDCPT-ZKHCSVRISA-N ClC=1C=C(C=CC=1OC)[C@@H]1CC[C@H](CC1)CN(C(=O)[C@@H]1CC[C@H](CC1)C(=O)O)C1=CC(=CC=C1)C1=CN=C(S1)C1CC1 Chemical compound ClC=1C=C(C=CC=1OC)[C@@H]1CC[C@H](CC1)CN(C(=O)[C@@H]1CC[C@H](CC1)C(=O)O)C1=CC(=CC=C1)C1=CN=C(S1)C1CC1 MJOSTMRKWHDCPT-ZKHCSVRISA-N 0.000 claims 1
- ZALXWVHAFNQXAE-YROJFRDXSA-N ClC=1C=C(C=CC=1OC)[C@@H]1CC[C@H](CC1)CN(C(=O)[C@@H]1CC[C@H](CC1)C(=O)O)C1=CC(=CC=C1)C=1C=NN(C=1)C1CC1 Chemical compound ClC=1C=C(C=CC=1OC)[C@@H]1CC[C@H](CC1)CN(C(=O)[C@@H]1CC[C@H](CC1)C(=O)O)C1=CC(=CC=C1)C=1C=NN(C=1)C1CC1 ZALXWVHAFNQXAE-YROJFRDXSA-N 0.000 claims 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000005577 Gastroenteritis Diseases 0.000 claims 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims 1
- 102100038239 Protein Churchill Human genes 0.000 claims 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 claims 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000002353 alcoholic hepatitis Diseases 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- VALZSZJVEFACEZ-UHFFFAOYSA-N azetidine-3-carboxamide Chemical compound NC(=O)C1CNC1 VALZSZJVEFACEZ-UHFFFAOYSA-N 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 125000004069 aziridinyl group Chemical group 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 230000036952 cancer formation Effects 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 231100000504 carcinogenesis Toxicity 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000007870 cholestasis Effects 0.000 claims 1
- 231100000359 cholestasis Toxicity 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 125000004976 cyclobutylene group Chemical group 0.000 claims 1
- JUNQLKPNWOCCKR-UHFFFAOYSA-N cyclohexyl 3-methoxyazetidine-1-carboxylate Chemical compound COC1CN(C1)C(=O)OC1CCCCC1 JUNQLKPNWOCCKR-UHFFFAOYSA-N 0.000 claims 1
- AUELWJRRASQDKI-UHFFFAOYSA-N cyclohexyl carbamate Chemical compound NC(=O)OC1CCCCC1 AUELWJRRASQDKI-UHFFFAOYSA-N 0.000 claims 1
- MSLVDDNWZVDSHU-UHFFFAOYSA-N cyclohexyl n,n-dimethylcarbamate Chemical compound CN(C)C(=O)OC1CCCCC1 MSLVDDNWZVDSHU-UHFFFAOYSA-N 0.000 claims 1
- TXGKUBFOORPYOW-UHFFFAOYSA-N cyclohexyl n-cyclopropylcarbamate Chemical compound C1CCCCC1OC(=O)NC1CC1 TXGKUBFOORPYOW-UHFFFAOYSA-N 0.000 claims 1
- HJDKDBZBAJJYTJ-UHFFFAOYSA-N cyclohexyl n-propan-2-ylcarbamate Chemical compound CC(C)NC(=O)OC1CCCCC1 HJDKDBZBAJJYTJ-UHFFFAOYSA-N 0.000 claims 1
- 125000004980 cyclopropylene group Chemical group 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 208000009866 extrahepatic cholestasis Diseases 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 208000001024 intrahepatic cholestasis Diseases 0.000 claims 1
- 230000007872 intrahepatic cholestasis Effects 0.000 claims 1
- SXQFCVDSOLSHOQ-UHFFFAOYSA-N lactamide Chemical compound CC(O)C(N)=O SXQFCVDSOLSHOQ-UHFFFAOYSA-N 0.000 claims 1
- 208000018191 liver inflammation Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 208000037931 necrotizing enteritis Diseases 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- NJYYWQHQUOODDL-UHFFFAOYSA-N oxetane-3-carboxamide Chemical compound NC(=O)C1COC1 NJYYWQHQUOODDL-UHFFFAOYSA-N 0.000 claims 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471511P | 2017-03-15 | 2017-03-15 | |
| US201762471525P | 2017-03-15 | 2017-03-15 | |
| US201762471517P | 2017-03-15 | 2017-03-15 | |
| US62/471,511 | 2017-03-15 | ||
| US62/471,517 | 2017-03-15 | ||
| US62/471,525 | 2017-03-15 | ||
| US201762563502P | 2017-09-26 | 2017-09-26 | |
| US201762563488P | 2017-09-26 | 2017-09-26 | |
| US62/563,488 | 2017-09-26 | ||
| US62/563,502 | 2017-09-26 | ||
| PCT/US2018/022513 WO2018170182A1 (en) | 2017-03-15 | 2018-03-14 | Farnesoid x receptor agonists and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020514334A JP2020514334A (ja) | 2020-05-21 |
| JP2020514334A5 true JP2020514334A5 (enExample) | 2021-04-15 |
| JP7258763B2 JP7258763B2 (ja) | 2023-04-17 |
Family
ID=63523880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547663A Active JP7258763B2 (ja) | 2017-03-15 | 2018-03-14 | ファルネソイドｘ受容体アゴニストおよびその使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11236071B1 (enExample) |
| EP (2) | EP4596041A3 (enExample) |
| JP (1) | JP7258763B2 (enExample) |
| KR (1) | KR102588982B1 (enExample) |
| CN (1) | CN110637015B (enExample) |
| AU (1) | AU2018236275B2 (enExample) |
| BR (1) | BR112019019154A2 (enExample) |
| CA (1) | CA3056019A1 (enExample) |
| DK (1) | DK3609888T3 (enExample) |
| ES (1) | ES3049520T3 (enExample) |
| FI (1) | FI3609888T3 (enExample) |
| HR (1) | HRP20251322T1 (enExample) |
| IL (1) | IL269065B (enExample) |
| LT (1) | LT3609888T (enExample) |
| MX (1) | MX2019010907A (enExample) |
| PH (1) | PH12019502058A1 (enExample) |
| PL (1) | PL3609888T3 (enExample) |
| PT (1) | PT3609888T (enExample) |
| RS (1) | RS67372B1 (enExample) |
| SG (1) | SG11201908330PA (enExample) |
| SI (1) | SI3609888T1 (enExample) |
| SM (1) | SMT202600045T1 (enExample) |
| WO (1) | WO2018170182A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10626081B2 (en) | 2015-09-16 | 2020-04-21 | Metacrine, Inc. | Farnesoid X receptor agonists and uses thereof |
| EP3350165B1 (en) | 2015-09-16 | 2023-07-26 | Organovo, Inc. | Farnesoid x receptor agonists and uses thereof |
| EP3350166A4 (en) | 2015-09-16 | 2019-05-01 | Metacrine, Inc. | FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF |
| AU2018236275B2 (en) | 2017-03-15 | 2022-05-12 | Eli Lilly And Company | Farnesoid X receptor agonists and uses thereof |
| DK3596053T3 (da) | 2017-03-15 | 2023-09-25 | Organovo Inc | Farnesoid-x-receptoragonister og anvendelser deraf |
| KR102731925B1 (ko) | 2017-11-01 | 2024-11-18 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 멀티시클릭 화합물 |
| US11286252B2 (en) | 2017-11-01 | 2022-03-29 | Bristol-Myers Squibb Company | Alkene spirocyclic compounds as farnesoid X receptor modulators |
| WO2020061117A1 (en) * | 2018-09-18 | 2020-03-26 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| BR112021004931A2 (pt) * | 2018-09-18 | 2021-06-01 | Metacrine, Inc. | formas cristalinas de um agonista de receptor farnesoide x |
| CN113056264A (zh) * | 2018-09-18 | 2021-06-29 | 梅塔科林公司 | 法尼醇x受体激动剂及其用途 |
| EP3852748B1 (en) * | 2018-09-18 | 2025-09-03 | Eli Lilly and Company | Farnesoid x receptor agonists and uses thereof |
| WO2020061116A1 (en) * | 2018-09-18 | 2020-03-26 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| EP3870162A4 (en) * | 2018-10-24 | 2022-08-24 | Metacrine, Inc. | SSAO INHIBITORS AND USES THEREOF |
| US12319676B2 (en) | 2019-02-15 | 2025-06-03 | Bristol-Myers Squibb Company | Substituted amide compounds useful as farnesoid X receptor modulators |
| JP7465883B2 (ja) * | 2019-02-15 | 2024-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | ファルネソイドｘ受容体モジュレータとしての置換二環式化合物 |
| AR118050A1 (es) * | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
| JP7449300B2 (ja) * | 2019-02-15 | 2024-03-13 | ブリストル－マイヤーズ スクイブ カンパニー | ファルネソイドｘ受容体モジュレータとして有用な置換アミド化合物 |
| MX2021009570A (es) * | 2019-02-15 | 2021-09-08 | Bristol Myers Squibb Co | Compuestos biciclicos sustituidos como moduladores del receptor de farnesoide x. |
| WO2021009332A1 (en) | 2019-07-18 | 2021-01-21 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| IL293892A (en) | 2020-01-15 | 2022-08-01 | Inserm Institut National De La Sant? Et De La Rech M?Dicale | Use of fxr agonists for treating an infection by hepatitis d virus |
| KR20220154801A (ko) * | 2020-03-18 | 2022-11-22 | 메타크린, 인크. | 질환의 치료를 위한 파르네소이드 x 수용체 작용제 |
| JP7664278B2 (ja) * | 2020-03-18 | 2025-04-17 | オルガノボ，インク． | ファルネソイドｘ受容体アゴニストの結晶質形態 |
| CN120227340A (zh) * | 2020-03-18 | 2025-07-01 | 伊莱利利公司 | 法尼醇x受体激动剂的制剂 |
| MX2023008365A (es) | 2021-01-14 | 2023-10-04 | Enyo Pharma | Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv. |
| TW202308629A (zh) | 2021-04-28 | 2023-03-01 | 法商Ｅｎｙｏ製藥公司 | 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效 |
| CN118178662B (zh) * | 2022-12-14 | 2026-03-20 | 深圳奥萨制药有限公司 | 含有法尼醇x受体激动剂的药物组合物及其用途 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4537900A (en) | 1999-05-17 | 2000-12-05 | Agouron Pharmaceuticals, Inc. | Glucagon antagonists/inverse agonists |
| EP1187810A2 (en) | 1999-05-25 | 2002-03-20 | Sepracor, Inc. | Heterocyclic analgesic compounds and their use |
| US6511980B2 (en) | 2000-05-05 | 2003-01-28 | Ortho Mcneil Pharmaceutical, Inc. | Substituted diamine derivatives useful as motilin antagonists |
| WO2001092226A1 (en) | 2000-05-25 | 2001-12-06 | Sepracor, Inc. | Heterocyclic analgesic compounds and method of use thereof |
| HUP0303360A2 (hu) | 2000-09-25 | 2004-01-28 | Actelion Pharmaceuticals Ltd. | Maláriaellenes hatású szubsztituált amino-aza-cikloalkánok és ezeket tartalmazó gyógyszerkészítmények |
| FR2815032B1 (fr) | 2000-10-10 | 2003-08-08 | Pf Medicament | Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations |
| FR2825706B1 (fr) | 2001-06-06 | 2003-12-12 | Pf Medicament | Nouveaux derives de benzothienyle ou d'indole, leur preparation et leur utilisation comme inhibiteurs de proteines prenyl transferase |
| FR2839974B1 (fr) | 2002-05-24 | 2004-07-16 | Pf Medicament | Derives de phenyl-furane ou de phenyl-thiophene,leur preparation et leur application a titre de medicament |
| WO2004009549A2 (en) | 2002-07-18 | 2004-01-29 | Actelion Pharmaceuticals Ltd | Piperidines useful for the treatment of central nervous system disorders |
| MXPA05003054A (es) | 2002-09-20 | 2005-05-27 | Pfizer Prod Inc | Ligandos de amida y sulfonamida para el receptor de estrogenos. |
| AU2003290796A1 (en) * | 2002-11-14 | 2004-06-15 | The Scripps Research Institute | Non-steroidal fxr agonists |
| WO2004046323A2 (en) | 2002-11-15 | 2004-06-03 | The Salk Institute For Biological Studies | Structure of the farnesoid x receptor ligand binding domain and methods of use therefor |
| US20050143449A1 (en) | 2002-11-15 | 2005-06-30 | The Salk Institute For Biological Studies | Non-steroidal farnesoid X receptor modulators and methods for the use thereof |
| GB0309781D0 (en) | 2003-04-29 | 2003-06-04 | Glaxo Group Ltd | Compounds |
| US7759348B2 (en) | 2003-07-30 | 2010-07-20 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| EP2316827B1 (en) | 2003-07-30 | 2016-01-27 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their use as therapeutic agents |
| US7754711B2 (en) | 2003-07-30 | 2010-07-13 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| WO2005058822A1 (en) | 2003-12-17 | 2005-06-30 | Actelion Pharmaceuticals Ltd | Substituted amino-cycloalkanes |
| JP2007530582A (ja) | 2004-03-26 | 2007-11-01 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 代謝可能部分を含む複素環抗ウイルス化合物およびその使用 |
| US20050272784A1 (en) | 2004-05-07 | 2005-12-08 | Xiaobing Li | Inhibitors of bacterial Type III protein secretion systems |
| JP2006199656A (ja) | 2005-01-24 | 2006-08-03 | Kowa Co | アミド基を有する環状アミン化合物 |
| MY144229A (en) | 2006-01-26 | 2011-08-15 | Xenon Pharmaceuticals Inc | Pyridazine derivatives and their use as therapeutic agents |
| CA2644369A1 (en) | 2006-03-28 | 2007-10-04 | Novartis Ag | Amide derivatives and their application for the treatment of g protein related diseases |
| US20080081824A1 (en) | 2006-09-29 | 2008-04-03 | Bristol-Myers Squibb Company | Substituted piperidines as modulators of chemokine receptor activity |
| WO2008065500A2 (en) | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Heteroaryl amides as type i glycine transport inhibitors |
| EP2234977A4 (en) | 2007-12-19 | 2011-04-13 | Boehringer Ingelheim Int | VIRAL POLYMERASE INHIBITORS |
| WO2010001869A1 (ja) | 2008-06-30 | 2010-01-07 | 武田薬品工業株式会社 | ４置換ベンゼン化合物およびその用途 |
| JP2010077109A (ja) | 2008-08-28 | 2010-04-08 | Takeda Chem Ind Ltd | 複素環化合物およびその用途 |
| AU2010272523A1 (en) | 2009-07-15 | 2012-02-02 | Merck Serono S.A. | Tetrazole derivatives |
| US8435980B2 (en) | 2009-07-15 | 2013-05-07 | Abbvie Inc. | Pyrrolopyridine inhibitors of kinases |
| FR2963005B1 (fr) | 2010-07-23 | 2012-08-17 | Sanofi Aventis | Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique |
| ME02754B (me) | 2011-03-23 | 2018-01-20 | Trevena Inc | Ligandi opioidnih receptora i postupci njihove upotrebe i pripreme |
| WO2013008706A1 (ja) | 2011-07-13 | 2013-01-17 | エム・テクニック株式会社 | 結晶子径を制御された微粒子の製造方法 |
| RU2543485C2 (ru) | 2013-02-26 | 2015-03-10 | Андрей Александрович Иващенко | Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения |
| GB201316824D0 (en) | 2013-09-23 | 2013-11-06 | R & D Vernalis Ltd | New Chemical Entities |
| US20150258052A1 (en) | 2014-03-13 | 2015-09-17 | Salk Institute For Biological Studies | Methods of using fexaramine and agents that increase sympathetic nervous system activity to promote browning of white adipose tissue |
| US10301268B2 (en) | 2014-03-13 | 2019-05-28 | The Salk Institute For Biological Studies | Analogs of fexaramine and methods of making and using |
| JP2017511304A (ja) | 2014-03-13 | 2017-04-20 | ソーク インスティチュート フォー バイオロジカル スタディーズ | フェキサラミン類似体ならびに作製方法および使用方法 |
| US20180116993A1 (en) | 2015-01-22 | 2018-05-03 | Xiamen University | Modulators of farnesoid x receptor and methods for the use thereof |
| AU2016233579A1 (en) | 2015-03-13 | 2017-10-12 | Salk Institute For Biological Studies | Treating latent autoimmune diabetes of adults with farnesoid X receptor agonists to activate intestinal receptors |
| WO2017018751A1 (ko) * | 2015-07-24 | 2017-02-02 | 동국대학교 산학협력단 | Blt 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 조성물 |
| EP3350166A4 (en) | 2015-09-16 | 2019-05-01 | Metacrine, Inc. | FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF |
| EP3350165B1 (en) | 2015-09-16 | 2023-07-26 | Organovo, Inc. | Farnesoid x receptor agonists and uses thereof |
| US10626081B2 (en) * | 2015-09-16 | 2020-04-21 | Metacrine, Inc. | Farnesoid X receptor agonists and uses thereof |
| WO2017049176A1 (en) | 2015-09-16 | 2017-03-23 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| KR102316645B1 (ko) | 2016-03-31 | 2021-10-25 | 가부시키가이샤 아데카 | 감광성 조성물 및 신규 화합물 |
| DE102016210851A1 (de) | 2016-06-17 | 2017-12-21 | Hamilton Bonaduz Ag | Fluidversorgungsschnittstelle mit Sicherheitsventil für eine Zellkulturanlage, Verwendung einer solchen Fluidversorgungsschnittstelle zur Bewirtschaftung von Zellkulturbehältern und Zellkultur-Bewirtschaftungsanlage |
| AU2018236275B2 (en) | 2017-03-15 | 2022-05-12 | Eli Lilly And Company | Farnesoid X receptor agonists and uses thereof |
| WO2018170173A1 (en) | 2017-03-15 | 2018-09-20 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| DK3596053T3 (da) | 2017-03-15 | 2023-09-25 | Organovo Inc | Farnesoid-x-receptoragonister og anvendelser deraf |
| WO2018170165A1 (en) | 2017-03-15 | 2018-09-20 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| US20200131132A1 (en) | 2017-03-15 | 2020-04-30 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| WO2020060007A1 (ko) | 2018-09-17 | 2020-03-26 | 엘지전자 주식회사 | 5g 이동통신에서 pdu 세션을 핸들링하는 방법 및 무선 기기 |
| US20220047553A1 (en) | 2018-09-18 | 2022-02-17 | Metacrine, Inc. | Farnesoid x receptor agonists for the treatment of disease |
| WO2020061117A1 (en) | 2018-09-18 | 2020-03-26 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| CN113056264A (zh) | 2018-09-18 | 2021-06-29 | 梅塔科林公司 | 法尼醇x受体激动剂及其用途 |
| EP3852748B1 (en) * | 2018-09-18 | 2025-09-03 | Eli Lilly and Company | Farnesoid x receptor agonists and uses thereof |
| WO2020061116A1 (en) | 2018-09-18 | 2020-03-26 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| WO2020061118A1 (en) | 2018-09-18 | 2020-03-26 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
-
2018
- 2018-03-14 AU AU2018236275A patent/AU2018236275B2/en active Active
- 2018-03-14 DK DK18768017.8T patent/DK3609888T3/da active
- 2018-03-14 CN CN201880032548.0A patent/CN110637015B/zh active Active
- 2018-03-14 RS RS20251107A patent/RS67372B1/sr unknown
- 2018-03-14 HR HRP20251322TT patent/HRP20251322T1/hr unknown
- 2018-03-14 MX MX2019010907A patent/MX2019010907A/es unknown
- 2018-03-14 PT PT187680178T patent/PT3609888T/pt unknown
- 2018-03-14 ES ES18768017T patent/ES3049520T3/es active Active
- 2018-03-14 KR KR1020197030348A patent/KR102588982B1/ko active Active
- 2018-03-14 SG SG11201908330P patent/SG11201908330PA/en unknown
- 2018-03-14 CA CA3056019A patent/CA3056019A1/en active Pending
- 2018-03-14 FI FIEP18768017.8T patent/FI3609888T3/fi active
- 2018-03-14 US US16/494,272 patent/US11236071B1/en active Active
- 2018-03-14 SM SM20260045T patent/SMT202600045T1/it unknown
- 2018-03-14 LT LTEPPCT/US2018/022513T patent/LT3609888T/lt unknown
- 2018-03-14 SI SI201831268T patent/SI3609888T1/sl unknown
- 2018-03-14 EP EP25178479.9A patent/EP4596041A3/en active Pending
- 2018-03-14 JP JP2019547663A patent/JP7258763B2/ja active Active
- 2018-03-14 WO PCT/US2018/022513 patent/WO2018170182A1/en not_active Ceased
- 2018-03-14 BR BR112019019154A patent/BR112019019154A2/pt not_active IP Right Cessation
- 2018-03-14 EP EP18768017.8A patent/EP3609888B1/en active Active
- 2018-03-14 PL PL18768017.8T patent/PL3609888T3/pl unknown
- 2018-03-14 IL IL269065A patent/IL269065B/en unknown
-
2019
- 2019-09-10 PH PH12019502058A patent/PH12019502058A1/en unknown
-
2021
- 2021-11-30 US US17/538,394 patent/US20220089575A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020514333A5 (enExample) | ||
| HRP20251322T1 (hr) | Agonisti receptora farnesoid x i njihova upotreba | |
| JP6464384B2 (ja) | キナーゼ阻害剤 | |
| JP2018531289A5 (enExample) | ||
| RU2018107694A (ru) | 1,3,4-оксадиазольные производные соединения в качестве ингибитора гистондеацетилазы 6 и фармацевтическая композиция, содержащая их | |
| JP6409001B2 (ja) | Ｈｂｖ感染に対する新規抗ウイルス剤 | |
| JP2011526930A5 (enExample) | ||
| JP2012504141A5 (enExample) | ||
| JP2020537657A5 (enExample) | ||
| HRP20151317T1 (hr) | Spojevi koji pokazuju aktivnost prema antagonistima muskarinskog receptora i beta2 adrenergiäśnog receptora | |
| HRP20240157T1 (hr) | Deuterirani derivati lanifibranora | |
| JP2019519598A5 (enExample) | ||
| HRP20230052T1 (hr) | Spojevi derivata 1,3,4-oksadiazol sulfonamida kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži | |
| CA2961870A1 (en) | Diaryl urea derivatives as p38 kinase inhibitors | |
| GB2461629A (en) | Phenoxy acetic acids as atagonists of prostaglandin D2 receptors | |
| JP2011500621A5 (enExample) | ||
| JP2022500392A5 (enExample) | ||
| JP2019531346A (ja) | 甲状腺関連副作用を低下させる方法 | |
| JP2021519776A5 (enExample) | ||
| CN113272298B (zh) | 用于治疗呼吸系统疾病的化合物和组合物 | |
| JP7143295B2 (ja) | ピペリジン－２，６－ジオン誘導体及びクローン病の治療 | |
| JP2019530674A5 (enExample) | ||
| JP6314129B2 (ja) | グアニジノ安息香酸エステル化合物 | |
| JP2019505502A5 (enExample) | ||
| SK7662002A3 (en) | Comminuted form of (s)-2-ethoxy -3-[4-(2-{4- methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid |